Cryptococcosis is an invasive infection that accounts for 15% of AIDS-related fatalities. Still, treating cryptococcosis remains a significant challenge due to the poor availability of effective antifungal therapies and emergence of drug resistance. Interestingly, protease inhibitor components of antiretroviral therapy regimens have shown some clinical benefits in these opportunistic infections. We investigated Major aspartyl peptidase 1 (May1), a secreted Cryptococcus neoformans protease, as a possible target for the development of drugs that act against both fungal and retroviral aspartyl proteases. Here, we describe the biochemical characterization of May1, present its high-resolution X-ray structure, and provide its substrate specificity analysis. Through combinatorial screening of 11,520 compounds, we identified a potent inhibitor of May1 and HIV protease. This dual-specificity inhibitor exhibits antifungal activity in yeast culture, low cytotoxicity, and low off-target activity against host proteases and could thus serve as a lead compound for further development of May1 and HIV protease inhibitors.

Chan Zuckerberg Biohub 499 Illinois Street San Francisco California 94158 United States

Department of Biochemistry and Biophysics University of California San Francisco UCSF Genentech Hall 600 16th St Rm N374 San Francisco California 94158 United States

Department of Biochemistry Faculty of Science Charles UniversityHlavova 8 Prague 2 12843 Czech Republic

Department of Chemical Biology and Bioimaging Wroclaw University of Science and Technology Wybrzeze Wyspianskiego 27 Wroclaw 50 370 Poland

Department of Pharmaceutical Chemistry University of California San Francisco UCSF Genentech Hall 600 16th St Rm S512 San Francisco California 94158 United States

Department of Physical and Macromolecular Chemistry Faculty of Science Charles UniversityHlavova 8 Prague 2 12843 Czech Republic

Institute of Molecular Genetics of the Czech Academy of Sciences Vídeňská 1083 Prague 4 14220 Czech Republic

Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences Flemingovo n 2 Prague 6 16610 Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc21018560

003      

CZ-PrNML

005      

20210830100135.0

007      

ta

008      

210728s2021 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1021/acs.jmedchem.0c02177 $2 doi

035    __

$a (PubMed)34006103

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Kryštůfek, Robin $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 6 16610, Czech Republic $u Department of Physical and Macromolecular Chemistry, Faculty of Science, Charles UniversityHlavova 8, Prague 2 12843, Czech Republic

245    10

$a Re-emerging Aspartic Protease Targets: Examining Cryptococcus neoformans Major Aspartyl Peptidase 1 as a Target for Antifungal Drug Discovery / $c R. Kryštůfek, P. Šácha, J. Starková, J. Brynda, M. Hradilek, E. Tloušt'ová, J. Grzymska, W. Rut, MJ. Boucher, M. Drąg, P. Majer, M. Hájek, P. Řezáčová, HD. Madhani, CS. Craik, J. Konvalinka

520    9_

$a Cryptococcosis is an invasive infection that accounts for 15% of AIDS-related fatalities. Still, treating cryptococcosis remains a significant challenge due to the poor availability of effective antifungal therapies and emergence of drug resistance. Interestingly, protease inhibitor components of antiretroviral therapy regimens have shown some clinical benefits in these opportunistic infections. We investigated Major aspartyl peptidase 1 (May1), a secreted Cryptococcus neoformans protease, as a possible target for the development of drugs that act against both fungal and retroviral aspartyl proteases. Here, we describe the biochemical characterization of May1, present its high-resolution X-ray structure, and provide its substrate specificity analysis. Through combinatorial screening of 11,520 compounds, we identified a potent inhibitor of May1 and HIV protease. This dual-specificity inhibitor exhibits antifungal activity in yeast culture, low cytotoxicity, and low off-target activity against host proteases and could thus serve as a lead compound for further development of May1 and HIV protease inhibitors.

650    _2

$a antifungální látky $x chemie $x metabolismus $x farmakologie $7 D000935

650    _2

$a aspartátové proteasy $x antagonisté a inhibitory $x genetika $x metabolismus $7 D057055

650    _2

$a vazebná místa $7 D001665

650    _2

$a katalytická doména $7 D020134

650    _2

$a Cryptococcus neoformans $x enzymologie $7 D003455

650    _2

$a krystalografie rentgenová $7 D018360

650    _2

$a preklinické hodnocení léčiv $7 D004353

650    _2

$a fungální proteiny $x antagonisté a inhibitory $x genetika $x metabolismus $7 D005656

650    _2

$a houby $x účinky léků $7 D005658

650    _2

$a HIV $x enzymologie $7 D006678

650    _2

$a HIV-proteasa $x chemie $x metabolismus $7 D016333

650    _2

$a simulace molekulární dynamiky $7 D056004

650    _2

$a rekombinantní proteiny $x biosyntéza $x chemie $x izolace a purifikace $7 D011994

650    _2

$a vztahy mezi strukturou a aktivitou $7 D013329

650    _2

$a substrátová specifita $7 D013379

655    _2

$a časopisecké články $7 D016428

655    _2

$a Research Support, N.I.H., Extramural $7 D052061

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Šácha, Pavel $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 6 16610, Czech Republic $u Department of Biochemistry, Faculty of Science, Charles UniversityHlavova 8, Prague 2 12843, Czech Republic

700    1_

$a Starková, Jana $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 6 16610, Czech Republic

700    1_

$a Brynda, Jiří $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 6 16610, Czech Republic $u Institute of Molecular Genetics of the Czech Academy of Sciences, Vídeňská 1083, Prague 4 14220, Czech Republic

700    1_

$a Hradilek, Martin $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 6 16610, Czech Republic

700    1_

$a Tloušt'ová, Eva $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 6 16610, Czech Republic

700    1_

$a Grzymska, Justyna $u Department of Chemical Biology and Bioimaging, Wroclaw University of Science and Technology, Wybrzeze Wyspianskiego 27, Wroclaw 50-370, Poland

700    1_

$a Rut, Wioletta $u Department of Chemical Biology and Bioimaging, Wroclaw University of Science and Technology, Wybrzeze Wyspianskiego 27, Wroclaw 50-370, Poland

700    1_

$a Boucher, Michael J $u Department of Biochemistry & Biophysics, University of California, San Francisco, UCSF Genentech Hall, 600 16th St Rm N374, San Francisco, California 94158, United States

700    1_

$a Drąg, Marcin $u Department of Chemical Biology and Bioimaging, Wroclaw University of Science and Technology, Wybrzeze Wyspianskiego 27, Wroclaw 50-370, Poland

700    1_

$a Majer, Pavel $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 6 16610, Czech Republic

700    1_

$a Hájek, Miroslav $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 6 16610, Czech Republic

700    1_

$a Řezáčová, Pavlína $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 6 16610, Czech Republic $u Institute of Molecular Genetics of the Czech Academy of Sciences, Vídeňská 1083, Prague 4 14220, Czech Republic

700    1_

$a Madhani, Hiten D $u Department of Biochemistry & Biophysics, University of California, San Francisco, UCSF Genentech Hall, 600 16th St Rm N374, San Francisco, California 94158, United States $u Chan-Zuckerberg Biohub, 499 Illinois Street, San Francisco, California 94158, United States

700    1_

$a Craik, Charles S $u Department of Pharmaceutical Chemistry, University of California San Francisco, UCSF Genentech Hall, 600 16th St Rm S512, San Francisco, California 94158, United States

700    1_

$a Konvalinka, Jan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 6 16610, Czech Republic $u Department of Biochemistry, Faculty of Science, Charles UniversityHlavova 8, Prague 2 12843, Czech Republic

773    0_

$w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 64, č. 10 (2021), s. 6706-6719

856    41

$u https://pubmed.ncbi.nlm.nih.gov/34006103 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20210728 $b ABA008

991    __

$a 20210830100135 $b ABA008

999    __

$a ok $b bmc $g 1689605 $s 1139006

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2021 $b 64 $c 10 $d 6706-6719 $e 20210518 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049

GRA    __

$a F32 AI152270 $p NIAID NIH HHS $2 United States

GRA    __

$a R01 AI100272 $p NIAID NIH HHS $2 United States

GRA    __

$a T32 HL007185 $p NHLBI NIH HHS $2 United States

GRA    __

$a P50 GM082250 $p NIGMS NIH HHS $2 United States

LZP    __

$a Pubmed-20210728